Clinical Trial Update: GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19) [Phase 2]

View source ↗

Summary

Phase 2 trial of GLS-1027 to prevent severe pneumonitis from SARS-CoV-2 infection (COVID-19) has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumonitis

Drugs mentioned

• GLS-1027

Snippet

Sponsor: GeneOne Life Science, Inc. | Conditions: Pneumonitis, SARS-CoV Infection | Phase 2 | Status: COMPLETED | Results posted: 2025-04-11